NCT01690520 - Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes | Biotech Hunter

Enrollment

163

Participants

Timeline

Start Date

December 11, 2012

Primary Completion Date

September 18, 2018

Study Completion Date

May 29, 2020

Conditions

Acute Biphenotypic LeukemiaAcute Lymphoblastic Leukemia in RemissionAcute Myeloid Leukemia in RemissionChronic Myelogenous LeukemiaMyelodysplastic Syndrome

Interventions

DRUG

Cyclophosphamide

Given IV

DRUG

Cyclosporine

Given IV or PO

BIOLOGICAL

Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion

Given IV

DRUG

Fludarabine Phosphate

Given IV

DRUG

Mycophenolate Mofetil

Given IV or PO

DRUG

Thiotepa

Given IV

RADIATION

Total-Body Irradiation

Undergo high dose or middle intensity TBI

PROCEDURE

Umbilical Cord Blood Transplantation

Undergo single-unit or double-unit unmanipulated umbilical cord blood transplant

Trial Locations (8)

10029

Mount Sinai Hospital, New York

27710

Duke University Medical Center, Durham

44195

Cleveland Clinic Foundation, Cleveland

91010

City of Hope Comprehensive Cancer Center, Duarte

94304

Stanford Cancer Institute Palo Alto, Palo Alto

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

80217-3364

University of Colorado, Denver

02215

Dana-Farber Cancer Institute, Boston